Please login to the form below

Not currently logged in
Email:
Password:

CML

This page shows the latest CML news and features for those working in and with pharma, biotech and healthcare.

NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia

NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia

There are an estimated 830 new cases of CML a year in England and Wales, with most patients needing lifelong treatment and management. ... decades, TKIs have been the mainstay of treatment for CML, however, over time patients often have to switch their

Latest news

More from news
Approximately 5 fully matching, plus 51 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    as myelodysplastic syndrome (MDS), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML) and solid tumours.

  • Deal Watch January 2017 Deal Watch January 2017

    With an enterprise value of $5.2bn this acquisition brings access to Iclusig (ponatinib), approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), as well as brigatinib in phase

  • Deal Watch May 2016 Deal Watch May 2016

    In addition Incyte was granted an exclusive licence to Inclusig [the only approved BCR-ABL inhibitor with activity against the T315I mutation approved in Europe for chronic myeloid leukaemia (CML) and

  • Seismic shifts: Hepatitis C and payers Seismic shifts: Hepatitis C and payers

    Analogues such as Glivec (imatanib) which transformed outcomes in CML need to be utilised to demonstrate that tough investment decisions by payers do pay off.

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Iclusig (ponatinib), inhibitor of BCR-ABL, for resistant and intolerant CML and Ph ALL (JP NDA). ... JP 9 other Asian countries (CML, chronic myeloid leukaemia ; Ph ALL, Philadelphia-chromosome positive acute lymphoblastic leukaemia).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Helen Parfitt joins Research Partnership Helen Parfitt joins Research Partnership

    She will also focus on the firm’s recently expanded oncology portfolio, which has added squamous cell carcinoma of the head and neck (SCCHN) and chronic myeloid leukaemia (CML) to its

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
SEVEN STONES COLLECTIVE

Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....